{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:31:19Z","timestamp":1793633479063,"version":"4.5.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011332","name":"Innovation Science and Economic Development Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omtn.2026.103076","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:43:17Z","timestamp":1787928197000},"page":"103076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3294-2952","authenticated-orcid":false,"given":"Matthew J.","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas G.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haritha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Karpov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstin","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliam Teixeira","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha R.","family":"Elford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Krishnan","family":"Gopalakrishna Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Marcusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4033-3577","authenticated-orcid":false,"given":"Natalia","family":"Martin Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103076_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103076_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103076_bib3","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R120.002309","article-title":"The Peptide Vaccine of the Future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.omtn.2026.103076_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103076_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103076_bib6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omtn.2026.103076_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.1995.tb44729.x","article-title":"Potential DNA vaccine integration into host cell genome","volume":"772","author":"Nichols","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.omtn.2026.103076_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ado5937","article-title":"Linking vaccine adjuvant mechanisms of action to function","volume":"10","author":"Ben-Akiva","year":"2025","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103076_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103076_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103076_bib13","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2026.103076_bib14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103076_bib15","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103076_bib16","doi-asserted-by":"crossref","first-page":"30701","DOI":"10.1021\/acsnano.4c09902","article-title":"Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo","volume":"18","author":"Luo","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103076_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.983000","article-title":"mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model","volume":"13","author":"Sittplangkoon","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib19","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103076_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib21","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/j.ymthe.2022.07.007","article-title":"mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells","volume":"30","author":"Bevers","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103076_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41551-023-01082-6","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.omtn.2026.103076_bib23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103076_bib24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib25","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103076_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10680","article-title":"Influenza A virus targets a cGAS-independent STING pathway that controls enveloped RNA viruses","volume":"7","author":"Holm","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103076_bib27","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","article-title":"Systemic vaccination induces CD8(+) T cells and remodels the tumor microenvironment","volume":"185","author":"Baharom","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s43018-024-00889-9","article-title":"Systemic IFN-I combined with topical TLR7\/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells","volume":"6","author":"Sanlorenzo","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omtn.2026.103076_bib29","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.4049\/jimmunol.0802982","article-title":"IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity","volume":"182","author":"Sikora","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103076_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103076_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103076_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2026.103076_bib34","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103076_bib35","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1128\/jvi.69.4.2297-2305.1995","article-title":"Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes","volume":"69","author":"Gairin","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2026.103076_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1006\/viro.1997.8627","article-title":"The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules","volume":"234","author":"Hudrisier","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2026.103076_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O","article-title":"Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection","volume":"28","author":"Oxenius","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib38","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103076_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0092-8674(91)90164-T","article-title":"Ablation of \u201ctolerance\u201d and induction of diabetes by virus infection in viral antigen transgenic mice","volume":"65","author":"Ohashi","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nm1176","article-title":"Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease","volume":"11","author":"Lang","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103076_bib41","article-title":"Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103076_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113047","article-title":"Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control","volume":"42","author":"Guo","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103076_bib43","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/0008-5472.CAN-11-3019","article-title":"Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice","volume":"72","author":"Hurez","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103076_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01699-24","article-title":"Lipid nanoparticles as adjuvant of norovirus VLP vaccine augment cellular and humoral immune responses in a TLR9- and type I IFN-dependent pathway","volume":"98","author":"Dai","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2026.103076_bib45","doi-asserted-by":"crossref","first-page":"33058","DOI":"10.1021\/acsnano.4c08490","article-title":"Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response","volume":"18","author":"Dowell","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103076_bib46","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","article-title":"Innate immune responses against mRNA vaccine promote cellular immunity through IFN-beta at the injection site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103076_bib47","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1089\/jir.2006.26.804","article-title":"Blocking monoclonal antibodies specific for mouse IFN-alpha\/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection","volume":"26","author":"Sheehan","year":"2006","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.omtn.2026.103076_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.103076_bib49","doi-asserted-by":"crossref","first-page":"18758","DOI":"10.1021\/acsnano.3c02251","article-title":"An Ionizable Lipid Material with a Vitamin E Scaffold as an mRNA Vaccine Platform for Efficient Cytotoxic T Cell Responses","volume":"17","author":"Oyama","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103076_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-026-03099-z","article-title":"mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression","author":"Marks","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103076_bib51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-026-10353-6","article-title":"mRNA vaccines engage unconventional pathways in CD8(+) T cell priming","volume":"654","author":"Jo","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103076_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103076_bib53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103076_bib54","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.immuni.2023.06.007","article-title":"TCR-independent CD137 (4-1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation","volume":"56","author":"Pichler","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103076_bib55","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib56","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","article-title":"CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103076_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103076_bib58","article-title":"Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103076_bib59","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1172\/JCI77053","article-title":"Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer","volume":"124","author":"Eruslanov","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103076_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.devcel.2024.10.010","article-title":"A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression","volume":"60","author":"Tang","year":"2025","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","article-title":"Interferon-stimulated neutrophils as a predictor of immunotherapy response","volume":"42","author":"Benguigui","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib62","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103076_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125520","article-title":"Process development of tangential flow filtration and sterile filtration for manufacturing of mRNA-lipid nanoparticles: A study on membrane performance and filtration modeling","volume":"675","author":"Wu","year":"2025","journal-title":"Int. J. Pharm."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:16:39Z","timestamp":1793632599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2162253126002477"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103076","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8+ T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103076"}}